Compare KBH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | KNSA |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.4B |
| IPO Year | 1987 | 2018 |
| Metric | KBH | KNSA |
|---|---|---|
| Price | $63.79 | $44.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $63.91 | $52.33 |
| AVG Volume (30 Days) | ★ 1.2M | 598.3K |
| Earning Date | 03-23-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.15 | 0.47 |
| Revenue | ★ $6,236,214,000.00 | $597,973,000.00 |
| Revenue This Year | N/A | $62.99 |
| Revenue Next Year | $6.74 | $33.30 |
| P/E Ratio | ★ $10.32 | $95.77 |
| Revenue Growth | N/A | ★ 55.68 |
| 52 Week Low | $48.90 | $18.12 |
| 52 Week High | $68.71 | $45.50 |
| Indicator | KBH | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 58.64 |
| Support Level | $59.89 | $42.00 |
| Resistance Level | $62.84 | $45.01 |
| Average True Range (ATR) | 2.04 | 1.58 |
| MACD | 0.56 | 0.12 |
| Stochastic Oscillator | 98.38 | 80.25 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.